Stockwatch

Date	Sym	Type	Headline
2024-04-22 06:00	UU:AKRO	News Release200	6 Stocks Positioned to Soar as Investors Focus on MASH
2024-03-08 16:02	UU:AKRO	News Release200	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-03-07 16:01	UU:AKRO	News Release200	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
2024-03-05 21:14	UU:AKRO	News Release200	Akero Therapeutics Announces Pricing of Public Offering of Common Stock
2024-03-04 16:21	UU:AKRO	News Release200	Akero Therapeutics Announces Proposed Public Offering of Common Stock
2024-03-04 06:00	UU:AKRO	News Release200	Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
2024-02-29 08:00	UU:AKRO	News Release200	Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
2024-02-29 07:00	UU:AKRO	News Release200	Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-01-03 08:15	UU:AKRO	News Release200	Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 07:00	UU:AKRO	News Release200	Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
2023-11-13 07:00	UU:AKRO	News Release200	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-10 08:58	UU:AKRO	News Release200	Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD ¢ € ™s The Liver Meeting ‚ ® 2023
2023-11-08 07:00	UU:AKRO	News Release200	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
2023-10-17 16:05	UU:AKRO	News Release200	Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
2023-10-10 07:00	UU:AKRO	News Release200	Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip
2023-10-09 16:05	UU:AKRO	News Release200	Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
2023-10-04 08:00	UU:AKRO	News Release200	Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
2023-08-31 07:00	UU:AKRO	News Release200	Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
2023-08-28 07:00	UU:AKRO	News Release200	Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
2023-08-11 06:00	UU:AKRO	News Release200	Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-06-23 07:00	UU:AKRO	News Release200	Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
2023-06-05 07:00	UU:AKRO	News Release200	Akero Therapeutics ¢ € ™ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
2023-06-01 16:05	UU:AKRO	News Release200	Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
2023-05-31 08:00	UU:AKRO	News Release200	Akero Therapeutics to Present at the Jefferies Healthcare Conference
2023-05-16 18:54	UU:AKRO	News Release200	Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
2023-05-15 07:00	UU:AKRO	News Release200	Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update